Sanofi expects Zantac arbitration case with Boehringer Ingelheim to be resolved early this year

After years of Zantac heartburn medication legal action, French pharma Sanofi is seeing a resolution to at least some of the litigation.

In Q4 guidance released Wednesday, Sanofi said it expects the obligations and indemnification rights being disputed through arbitration with Boehringer Ingelheim will be resolved this year, with earliest at the end of Q1. Sanofi bought Zantac from Boehringer in 2017.